Burlington, Ontario, Canada
Too many breakthrough technologies never reach patients. Not because the science failed, but because the company failed before the science had the opportunity to succeed. After more than 25 years in biotechnology, I’ve seen remarkable innovations remain on the bench because early-stage companies often lack the capital, operational experience and strategic guidance needed to transform great science into successful businesses. That realization ultimately led me to create Omnium Global. My career has taken me from multinational pharmaceutical companies to biotechnology startups, CDMOs and venture-backed growth companies across North America, Europe, Asia-Pacific and Latin America. I’ve worked with organizations in more than 30 countries, leading scientific, operational and commercial teams through product development, manufacturing scale-up, fundraising, licensing, strategic partnerships and M&A. My first exit, the sale of Natrix Separations to Merck (MilliporeSigma) reinforced my conviction that experienced execution can dramatically change the trajectory of a company. It also gave me the opportunity to build Omnium Global around a simple idea: identify exceptional science, invest alongside ambitious founders and help build companies capable of delivering meaningful impact for patients. Today, my work focuses on venture creation, company building and long-term value creation across biotechnology. I am particularly passionate about differentiated therapeutics, drug delivery technologies, advanced biomanufacturing, capital-efficient development strategies, including 505(b)(2), and innovations capable of expanding access to healthcare globally. I am the founder of Omnium Global and a co-founder of Enable Biotech and 20/20 OptimEyes Technologies. Throughout my career, I have participated in more than US$1.5 billion in strategic transactions spanning licensing, manufacturing partnerships and M&A. I believe biotechnology has a responsibility that extends beyond financial returns. The companies we build today should not only create value for founders and investors, but also improve lives, strengthen healthcare systems and make innovative medicines more accessible around the world. If you’re building technology with the potential to make a meaningful difference, I’d be delighted to connect.
Founder & CEO | Omnium Global Omnium Global is a life sciences venture studio dedicated to identifying, investing in and building biotechnology companies with the potential to improve patient care and expand access to innovative healthcare worldwide. We invest selectively in companies developing differentiated therapeutics, drug delivery technologies, advanced biomanufacturing platforms and other enabling life sciences innovations. Our philosophy is simple: exceptional science deserves exceptional execution. Rather than building a large portfolio, we concentrate our efforts on a small number of companies where our investment, operating experience and long-term partnership can meaningfully influence outcomes. We work alongside founders to accelerate scientific development, manufacturing readiness, regulatory strategy, fundraising, strategic partnerships and commercialization, helping transform promising technologies into enduring businesses. Our investment thesis is guided by three principles: • Build companies around science capable of making a meaningful difference for patients. • Create value through disciplined execution, experienced leadership and long-term partnership. • Support technologies that can improve access to healthcare through smarter development, scalable manufacturing and capital-efficient innovation. Current portfolio and investment activities include companies developing ophthalmic therapeutics, conjugate vaccines, advanced drug delivery, biomanufacturing technologies and next-generation platform technologies, with additional investments currently under evaluation. My responsibilities include P&L management, investment strategy, venture creation, portfolio development, fundraising, strategic partnerships, corporate development and long-term value creation across the Omnium Global portfolio. And yes, I actually love analyzing the markets, building valuation models and writing strategic investment memos! -- Let’s talk! --
Omnium Global is a venture studio that supports life sciences companies with fundraising, commercial strategy, and operational execution. We take hands-on leadership in our portfolio companies, turning strong science into partnerable assets. Rather than acting as a traditional investor, Omnium partners closely with founders by deploying not only capital, but also leadership and operational expertise to transform early-stage scientific ideas into fundable, scalable ventures. Through our extensive global network of industry leaders, investors, and technical experts, we unlock opportunities, accelerate development, and optimize outcomes for every venture we support.
As CCO, I lead global business development, CDMO oversight, marketing, and strategic partnerships for Fina BioSolutions, a leader in CRM197 production and low-cost conjugate vaccine development. I work with vaccine developers, CDMOs, and public health agencies to accelerate access to affordable vaccines worldwide. Key contributions include: • Holding full P&L responsibility and leading reporting activities to SK bioscience, our strategic investor • Driving global licensing and sales of CRM197 for commercial and global health applications • Leading the commercialization and potential spin-off of FinaXpress, our proprietary microbial expression platform optimized for high-yield protein production • Overseeing CDMO selection, tech transfer, and commercial GMP manufacturing of CRM197 and other recombinant proteins • Managing fermentation process development and scale-up activities to support clinical and commercial supply • Leading strategic proposals, and shaping Fina’s positioning as an enabler of low-cost biomanufacturing in LMICs
Providing strategic insights and data-driven guidance to biopharmaceutical clients across the value chain—from market landscape assessment and commercial strategy to manufacturing capacity planning and facility design. I contribute to BioPlan’s global intelligence initiatives and thought leadership efforts, with a focus on bioprocessing innovation, CDMO strategy, and advanced therapeutics. Key activities include: • Advising clients on market entry, competitive positioning, and technology investment strategies in biologics and cell/gene therapy manufacturing • Supporting facility planning and operational strategy for CDMOs and biopharma manufacturers, including cost modeling and capacity optimization • Contributing to BioPlan’s Annual Survey of Biopharmaceutical Manufacturing and custom research engagements with actionable market intelligence • Collaborating on publications and presentations that shape industry dialogue around productivity, innovation, and access in global biomanufacturing
I am a co-founder, CCO, and Board Director of Enable Biotech — a purpose-built, new-generation CDMO based in Zug, Switzerland. We founded Enable to serve the unmet needs of early-stage innovators in Cell & Gene Therapy and Exosome Therapeutics — offering flexible, phase-adapted development and GMP manufacturing services specifically designed for clinical-stage companies. Enable provides: • Process development and GMP manufacturing for autologous and allogeneic gene-modified cell therapies • Process development and GMP manufacturing for exosome therapies • GMP cell banking (MCB, WCB) and production of mAbs and recombinant proteins for early-stage clinical trials • CMC program management, QA, and regulatory submission support We act as an extension of our clients’ teams — co-developing CMC and regulatory strategies, and advancing first-in-human and early clinical programs with maximum agility and capital efficiency. Our networked model combines a lean internal team with a best-in-class network of experts in CMC, Regulatory, Quality (QA/QP), and Engineering — enabling us to deliver world-class execution at a fraction of the overhead of traditional CDMOs. In my role, I contribute to overall company strategy and lead commercial, CMC, and service strategy across Enable’s core offerings — including autologous and allogeneic gene-modified cell therapies, exosome therapies, and GMP protein manufacturing. Drawing on my broader experience leading AI/ML-driven digital transformation projects in the life sciences sector, I help guide Enable’s adoption of modern, data-driven, and automated approaches to CMC operations, knowledge management, and client services — with a strong focus on efficiency and productivity improvements. Enable is building the CDMO that early-stage innovators truly need: flexible, partner-driven, and engineered for today’s capital environment.